Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial

Nivolumab is a human monoclonal antibody against the immune checkpoint receptor programmed death‐1, inhibiting binding to programmed death‐ligand 1 or 2 (PD‐L1 or PD‐L2). This phase 2 study evaluated the efficacy and safety of nivolumab in patients with advanced/recurrent uterine cervical cancer, ut...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Sci
Main Authors: Tamura, Kenji, Hasegawa, Kosei, Katsumata, Noriyuki, Matsumoto, Koji, Mukai, Hirofumi, Takahashi, Shunji, Nomura, Hiroyuki, Minami, Hironobu
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726684/
https://ncbi.nlm.nih.gov/pubmed/31348579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14148
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki